Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia

Stem Cell Investigation

Volumn 2016, Issue AUG, 2016, Pages

  Kimura, Shinya ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

ABL tyrosine kinase inhibitor (TKI); Chronic myeloid leukemia (CML); Discontinuation; Stop

Indexed keywords

ABELSON KINASE; ABELSON KINASE INHIBITOR; BCR ABL PROTEIN; DASATINIB; ENZYME INHIBITOR; IMATINIB; NILOTINIB; UNCLASSIFIED DRUG;

CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FRANCE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION;

EID: 84994877342     PISSN: None     EISSN: 23069759     Source Type: Journal    
DOI: 10.21037/sci.2016.07.08     Document Type: Review

References (27)

1. Sasaki K, Strom SS, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2015;2:e186-93.
2. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012;118:3123-7.
3. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
4. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35.
5. Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2015;2:e528-35.
6. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515-22.
7. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014;32:424-30.
8. Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 2015;90:910-4.
9. Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 2012;97:903-6.
10. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;24:1719-24.
11. Mahon FX, Richter J, Guilhot J, et al. Interim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: the EURO-SKI study. Available online: https://ash.confex.com/ash/2014/webprogram/Paper74060.html
12. Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007;13:7080-5.
13. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014;123:1353-60.
14. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123:494-500.
15. Rea D, Nicolini FE, Tulliez M, et al. Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: interim analysis of the STOP2G-TKI study with a minimum follow-up of 12months - on behalf of the French CML group Filmc. Available online: https://ash.confex.com/ash/2014/webprogram/Paper72021.html
16. Tsutsumi Y, Ito S, Ohigashi H, et al. Unplanned discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. Mol Clin Oncol 2016;4:89-92.
17. Richter J, Söderlund S, Lübking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol 2014;32:2821-3.
18. Ishii Y, Hagihara M, Kato A, et al. Musculoskeletal pain may be associated with imatinib withdrawal syndrome in chronic myeloid leukemia patients. Leuk Lymphoma 2015. [Epub ahead of print].
19. Breccia M, Efficace F, Sica S, et al. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk Res 2015;39:1055-9.
20. Kijima M, Gardiol N, Held W. Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo. PLoS One 2011;6:e27639.
21. Kreutzman A, Rohon P, Faber E, et al. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 2011;6:e23022.
22. Mizoguchi I, Yoshimoto T, Katagiri S, et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci 2013;104:1146-53.
23. Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009;94:135-9.
24. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-405.
25. Legros L, Rousselot P, Giraudier S, et al. Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. Blood 2012;120:1959-60.
26. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-84.
27. Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood 2016;128:17-23.